Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

12P - Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells

Date

21 Oct 2023

Session

Poster session 09

Topics

Tumour Immunology

Tumour Site

Presenters

Christine Schuberth-Wagner

Citation

Annals of Oncology (2023) 34 (suppl_2): S187-S214. 10.1016/S0923-7534(23)01931-2

Authors

C. Schuberth-Wagner1, I. Giese1, M. Kist1, N. Vashist1, S. Genßler1, B. Haack2, J. Weigandt1, M. Auer3, J. Wischhusen4, K. Klar3, E. Leo5, M. Haake1

Author affiliations

  • 1 Research, CatalYm GmbH, 82152 - Planegg-Martinsried/DE
  • 2 Obstetrics And Gynecology, University of Würzburg, 97080 - Würzburg/DE
  • 3 Translational Research, CatalYm GmbH, 82152 - Planegg-Martinsried/DE
  • 4 Obstetrics And Gynecology, University of Würzburg, 97070 - Würzburg/DE
  • 5 Clinical Research, CatalYm GmbH, 82152 - Planegg-Martinsried/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 12P

Background

Growth and differentiation factor 15 (GDF-15), a divergent member of the TGF-β superfamily, shows high expression during pregnancy. Beyond that, GDF-15 is induced in stressed and damaged tissues limiting inflammation. GDF-15 also functions as a prognostic marker in numerous cancers and was shown to be a key inhibitor of T-cell infiltration in solid tumors. However, the impact of GDF-15 on other immune cells in the tumor microenvironment (TME) is still poorly understood.

Methods

M1 and M2 macrophages were derived from either the human monocytic THP-1 cell line or monocytes from healthy donors by incubation with IFNγ and LPS (M1) or IL-4 and IL-13 (M2) in combination with or without GDF-15. Analysis was performed by Western Blot, flow cytometry and RT-qPCR. To investigate the role of GDF-15 in vivo we inoculated NOG mice subcutaneously with SK-Mel5 GDF15 -/- cells. On day 35/36 tumors were assessed on myeloid immune cell subpopulations by flow cytometry.

Results

Our initial studies have shown that monocytes are sensitive to GDF-15 mediated inhibition of tumor infiltration. Now we wanted to understand how GDF-15 affects the myeloid compartment beyond infiltration. In primary cells, GDF-15 exposure of monocytes during IFNγ or LPS induced M1 polarization led to a reduction of activation marker expression such as HLA-DR, CD80 and CD86 and an altered cytokine secretion profile. M2 macrophages did not show differences in their activation pattern. This effect was transferable to THP-1 derived M1 macrophages. TGF-ß was not able to exert this biologic effect. Activation was restored by addition of a GDF-15 neutralizing antibody. In vivo, GDF-15 had no direct effect on tumor growth, yet we observed that loss of GDF-15 altered the TME and led to an increase of activated myeloid cells such as M1 macrophages and dendritic cells.

Conclusions

GDF-15 secretion helps tumors to generate a TME that is poorly infiltrated by anti-tumoral immune cells. GDF-15 counteracts myeloid activation in the TME, a hallmark of initiation of antitumoral immune responses. By inducing a more pro-inflammatory tumor phenotype, anti-GDF-15 antibodies may synergize with other immunotherapeutic agents. A clinical phase 2 trial combining anti-GDF-15 (CTL-002) with anti-PD-1 (NCT04725474) is ongoing.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

CatalYm GmbH.

Funding

CatalYm GmbH.

Disclosure

C. Schuberth-Wagner: Financial Interests, Personal, Full or part-time Employment: CatalYm GmbH; Financial Interests, Personal, Stocks/Shares: CatalYm GmbH, Merck & Co; Financial Interests, Personal, Royalties: Rigontec GmbH; Non-Financial Interests, Advisory Role: RNHale GmbH. I. Giese, M. Kist, N. Vashist, S. Genßler, M. Auer, K. Klar: Financial Interests, Personal, Full or part-time Employment: CatalYm GmbH. J. Weigandt: Financial Interests, Personal, Full or part-time Employment, Scientist Role: Catalym; Financial Interests, Personal, Stocks/Shares, small number of shares held privately: AstraZeneca, Moderna. J. Wischhusen: Financial Interests, Personal, Advisory Board: CatalYm; Financial Interests, Personal, Stocks/Shares: CatalYm; Financial Interests, Personal, Advisory Board, Fees received via University of Würzburg as compensation for inventorship: CatalYm; Financial Interests, Institutional, Funding: CatalYm. E. Leo: Financial Interests, Personal, Advisory Board, Advisory role: T-knife GmbH; Financial Interests, Personal, Full or part-time Employment, CMO: CatalYm GmbH; Financial Interests, Personal, Stocks/Shares, Share options: CatalYm GmbH, T-knife GmbH. M. Haake: Financial Interests, Personal, Full or part-time Employment: CatalYm GmbH; Financial Interests, Personal, Stocks/Shares, Co-Founder: CatalYm GmbH; Financial Interests, Personal, Advisory Board: CatalYm GmbH; Non-Financial Interests, Other, Co-founder: CatalYm GmbH. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.